Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정혜경 | - |
dc.date.accessioned | 2016-08-29T12:08:42Z | - |
dc.date.available | 2016-08-29T12:08:42Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 2093-0879 | - |
dc.identifier.other | OAK-18468 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/231485 | - |
dc.description.abstract | Background/Aims The effect of proton pump inhibitors (PPI) in Asian functional dyspepsia (FD) patients has not been well established as in Western countries. DA-9701, a novel prokinetic agent, stimulates gastric emptying and modulates visceral hypersensitivity in vivo and in human studies. This study was conducted to compare the efficacy of DA-9701 with a conventional PPI in mono or combination therapy in patients with FD. Methods In this double-blind, randomized, non-inferiority trial, 389 patients diagnosed with FD using Rome III criteria were allocated among 3 groups: 30-mg DA-9701 t.i.d (means 3 times a day), 40-mg pantoprazole, and 30-mg DA-9701 t.i.d + 40-mg pantoprazole. The primary efficacy end-point was a global assessment of the patient binary response or response on a 5-Likert scale after 4 weeks. Results The global symptomatic improvement was 60.5% in the DA-9701 group, 65.6% in the pantoprazole group, and 63.5% in the DA- 9701 + pantoprazole group using a 5-Likert scale at week 4 with no significant difference among 3 groups (P = 0.685). Symptom improvement measured by binary outcome was significantly achieved in each of the 3 groups, but not different among groups. Patients in all treatment groups reported significant improvement in the response rate and symptoms according to FD subtypes and dyspepsia-related quality of life (P < 0.001), but there were no significant differences among the 3 groups. Conclusions DA-9701 improves global and individual symptoms and increases dyspepsia-specific quality of life in patients with FD. The efficacy of DA-9701 monotherapy is comparable with pantoprazole and there is no additive effect with combination of DA-9701 and pantoprazole in patients with FD. © 2016 The Korean Society of Neurogastroenterology and Motility. | - |
dc.language | English | - |
dc.publisher | Journal of Neurogastroenterology and Motility | - |
dc.subject | DA-9701 (Motilitone) | - |
dc.subject | Dyspepsia | - |
dc.subject | Proton pump inhibitor | - |
dc.title | Efficacy of da-9701 (motilitone) in functional dyspepsia compared to pantoprazole: A multicenter, randomized, double-blind, non-inferiority study | - |
dc.type | Article | - |
dc.relation.issue | 2 | - |
dc.relation.volume | 22 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.index | KCI | - |
dc.relation.startpage | 254 | - |
dc.relation.lastpage | 263 | - |
dc.relation.journaltitle | Journal of Neurogastroenterology and Motility | - |
dc.identifier.doi | 10.5056/jnm15178 | - |
dc.identifier.wosid | WOS:000373662200012 | - |
dc.identifier.scopusid | 2-s2.0-84964337357 | - |
dc.author.google | Jung H.-K. | - |
dc.author.google | Lee K.J. | - |
dc.author.google | Choi M.-G. | - |
dc.author.google | Park H. | - |
dc.author.google | Lee J.S. | - |
dc.author.google | Rhee P.-L. | - |
dc.author.google | Kim N. | - |
dc.author.google | Park K.S. | - |
dc.author.google | Choi S.C. | - |
dc.author.google | Lee O.Y. | - |
dc.author.google | Huh K.C. | - |
dc.author.google | Song G.A. | - |
dc.author.google | Hong S.J. | - |
dc.author.google | Sohn C.I. | - |
dc.author.google | Jung H.-Y. | - |
dc.author.google | Lee Y.C. | - |
dc.author.google | Rew J.S. | - |
dc.author.google | Jee S.R. | - |
dc.author.google | Kwon J.G. | - |
dc.contributor.scopusid | 정혜경(7403029723) | - |
dc.date.modifydate | 20230208112902 | - |